Phibro Animal Health Corporation last reported quarterly results on Nov 4, 2026, for Q1 FY2027 (the quarter ended Sep 30, 2026): revenue of $386.8 million (+6.3% year over year) and diluted EPS of $0.72. It usually reports 35–57 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 3, 2027.
Results for Q2 FY2027, the quarter ending around Dec 31, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Feb 4, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 35–57 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 4, 2026
35 days after quarter end
|
Q1 FY2027
ended Sep 30, 2026
|
387
+6.3%
|
30
+11.3%
|
0.72
+10.8%
|
|
Aug 26, 2026
57 days after quarter end
|
Q4 FY2026
ended Jun 30, 2026
|
397
+4.8%
|
22
+26.0%
|
0.53
+25.2%
|
|
May 6, 2026
36 days after quarter end
|
Q3 FY2026
ended Mar 31, 2026
|
384
+10.3%
|
24
+15.1%
|
0.59
+15.7%
|
|
Feb 4, 2026
35 days after quarter end
|
Q2 FY2026
ended Dec 31, 2025
|
374
+20.9%
|
27
+762.1%
|
0.67
+737.5%
|
|
Nov 5, 2025
36 days after quarter end
|
Q1 FY2026
ended Sep 30, 2025
|
364
+39.7%
|
27
+280.3%
|
0.65
+282.4%
|
|
Aug 27, 2025
58 days after quarter end
|
Q4 FY2025
ended Jun 30, 2025
|
379
+38.6%
|
17
+2190.4%
|
0.42
+2182.6%
|
|
May 7, 2025
37 days after quarter end
|
Q3 FY2025
ended Mar 31, 2025
|
348
+32.1%
|
21
+148.4%
|
0.51
+142.9%
|
|
Feb 5, 2025
36 days after quarter end
|
Q2 FY2025
ended Dec 31, 2024
|
309
+23.7%
|
3
+150.0%
|
0.08
+166.7%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PAHC (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Teaneck, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1069899
- Former names
- PHILIPP BROTHERS CHEMICALS INC (until May 14, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.